Acadia Pharmaceuticals Inc. (ACAD)
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system disorders. It is known for its flagship product, Nuplazid (pimavanserin), approved for the treatment of Parkinson's disease psychosis. The company's research and development efforts aim to address unmet medical needs in areas such as schizophrenia, dementia-related psychosis, and other neuropsychiatric conditions.
Company News
Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock. Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to ...Full story available on Benzinga.com
Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Some more academic heft is coming to the view that illegal immigration may be the surprise factor that’s keeping the economy running strong yet allowing inflation to cool down.
An analyst upgrade is sparking a rally in the drugmaker's shares today.